Cargando…
Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion
The Lassa virus (LASV) is endemic in West Africa and causes severe hemorrhagic Lassa fever in humans. The glycoprotein complex (GPC) of LASV is highly glycosylation-modified, with 11 N-glycosylation sites. All 11 N-linked glycan chains play critical roles in GPC cleavage, folding, receptor binding,...
Autores principales: | Dong, Siqi, Mao, Wenting, Liu, Yang, Jia, Xiaoying, Zhang, Yueli, Zhou, Minmin, Hou, Yuxia, Xiao, Gengfu, Wang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wuhan Institute of Virology, Chinese Academy of Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311258/ https://www.ncbi.nlm.nih.gov/pubmed/37059226 http://dx.doi.org/10.1016/j.virs.2023.04.003 |
Ejemplares similares
-
Screening and Identification of Lassa Virus Entry Inhibitors from a Fragment-Based Drug Discovery Library
por: Hou, Yuxia, et al.
Publicado: (2022) -
Comprehensive Interactome Analysis Reveals that STT3B Is Required for N-Glycosylation of Lassa Virus Glycoprotein
por: Zhu, Shenglin, et al.
Publicado: (2019) -
Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library
por: Cao, Junyuan, et al.
Publicado: (2021) -
Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19
por: Cao, Junyuan, et al.
Publicado: (2022) -
Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response
por: Zhu, Xueqin, et al.
Publicado: (2021)